AzTrials
AzTrials

Venous Leg Ulcer (VLU)ConvaVAC VLUNCT07342049

ConvaVAC™ Ag+ Negative Pressure Wound Therapy System in Chronic Wounds

A study testing ConvaVAC™ Ag+ Negative Pressure Wound Therapy System in people with Venous Leg Ulcer (VLU), run by ConvaTec Inc. at 7 sites in 2 countries.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Purpose of this study is to learn more about how safe and effective the ConvaVAC™ Ag+ wound therapy system is in treating certain types of long-lasting wounds, called chronic wounds. In this study, the focus is on Venous Leg Ulcers (VLUs). Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Venous Leg Ulcer (VLU)
What is being tested?
ConvaVAC™ Ag+ Negative Pressure Wound Therapy System
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
87 participants
Where
7 sitesin 2 countries
Study dates
12 Jan 2026to 30 Oct 2026
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • A wound which is amenable to NPWT and is a VLU as defined by CEAP Classification of C6 or C6R
  • Wounds that are clean or contaminated
  • Wounds with at least one sign or symptom of infection
  • Wounds that in the opinion of the investigator would benefit from an antimicrobial dressing
  • ≥18 years old at the time of consent

Who cannot join

  • Known sensitivities or allergies to components of the ConvaVAC™ Ag+ NPWT System
  • Ischemic wounds with necrotic tissue or eschar present that require sharp debridement
  • Wound is too small or too large based on wound dressing size (> 0.5cm2 and < 100cm2)
  • Wound depth >7cm
  • Wounds requiring concomitant use of DuoDERM® gel, hydrogels, petroleum-based creams/ ointment-/gels per the opinion of the investigator
  • Active chemotherapy, radiation therapy, or immunotherapy for cancer or completed treatment within the last 3 months
Show all 15Show fewer
  • Any active malignancy at site of dressing application
  • Exposed bone in target wound
  • Exposed blood vessels or nerves in target wound
  • Systemic infection and/or systemic inflammatory response syndrome (SIRS), sepsis
  • Cellulitis in target wound
  • Untreated deep tissue infection including but not limited to osteomyelitis, septic arthritis
  • Active Pregnancy
  • Subjects that in the opinion of the investigator are not suitable for enrollment
  • Vulnerable subjects as determined by ICH Harmonized Guideline, Good Clinical Practice E6(R2)

Trial locations and contacts

7 sites in 2 countries. Contact the study team or a site near you to ask about taking part.

7 sites in 2 countries

United Kingdom6 sites, 6 recruiting
  • Northumbria Healthcare NHS Foundation Trust

    Ashington, Northumberland, NE630HP

    Debera Drew, 01670859030, debera.drew@northumbria-healthcare.nhs.uk

    Louise Jones, 0191 2933019, Louise.Jones@northumbria-healthcare.nhs.uk

    Recruiting
  • Middlewood Partnership

    Bollington, Cheshire, SK10 5JH

    Pete Wilson, 01625 462 593, pete.wilson@nhs.net

    Thomas Fathers, thomas.fathers@nhs.net

    Recruiting
  • Dorset County Hospital NHS Foundation Trust

    Dorchester, Dorset, DT1 2JY

    Martin Longley, 01305 25 4115, martin.longley@dorsetgp.nhs.uk

    Ulysses Hechanova, Ulysses.Hechanova@dchft.nhs.uk

    Recruiting
  • Knutsford Medical Partnership

    Knutsford, Cheshire, WA16 9DX

    Thomas Morgan, 01565 743100, thomas.morgan@nhs.net

    Helen Hodgson, 01565 743100, h.hodgson1@nhs.net

    Recruiting
  • Nottingham University Hospitals NHS Trust

    Nottingham, Nottinghamshire, NG7 2UH

    Christopher Cruse, 0115 924 9924 ext. 80714, christopher.cruse@nhs.net

    David A Sidloff, Dr

    Recruiting
  • Assured Clinical Research Ltd

    Swaffham, Norfolk, PE37 7RD

    Fong Pham, +44 2035766111, fpham@assuredclinical.com

    Susan Davidson, sdavison@assuredclinical.com

    Recruiting

Other trials in United Kingdom

Chile1 site, 1 recruiting
  • ConvaCare Clinic

    Santiago, Santiago Metropolitan

    Jeison D Peñuela, +56934249429, jeisondavidpa@gmail.com

    Jocelyn Rojas

    Recruiting

Other trials in Chile

About this study

Official title: A Study to Determine the Safety and Performance of ConvaVAC™ Ag+ Negative Pressure Wound Therapy System in Chronic Wounds

Purpose of this study is to learn more about how safe and effective the ConvaVAC™ Ag+ wound therapy system is in treating certain types of long-lasting wounds, called chronic wounds. In this study, the focus is on Venous Leg Ulcers (VLUs). Chronic wounds are wounds that do not heal properly or take a long time to heal. They can cause pain, discomfort, and affect your day-to-day life. These types of wounds are also challenging for healthcare teams to treat and can take up a lot of healthcare resources. Venous Leg Ulcers (VLUs) are the most common type of chronic leg wound and affect about 1 in every 100 people. Usual treatments for VLUs include cleaning the wound, using special dressings, applying pressure (compression therapy), and sometimes using creams or dressings that contain silver to fight infection. This study is being done to see if the wound therapy system can help heal venous leg ulcers more effectively and safely.

Read the detailed description

Chronic wounds, also sometimes referred to as hard-to-heal wounds, are defined as wounds that do not transition through the normal phases of healing in a timely manner. These wounds reduce health-related quality-of-life (QoL) for the patient and pose a substantial burden on healthcare professionals (HCPs) and healthcare systems. The number of chronic wounds is rising. With a global prevalence of ~1.9 per 1,000 and 1-2% in developed countries, it is predicted that the incidence of chronic wounds will increase with the aging population. Wound care accounts for 2-4% of healthcare expenditure in Europe and costs $28 billion per year in the United States.

A significant contributing factor to the delayed healing of chronic wounds is the increased risk of infection. Evidence suggests that biofilm comprises at least 78% of chronic wounds. Biofilm is communities of microorganisms embedded in a matrix of extracellular polymeric substances. This matrix protects microorganisms from antibiotics, antiseptics and the host immune response. The development of biofilm in wounds elicits a sub-optimal host inflammatory response, and is a precursor of local infection. The presence of biofilm-forming microorganisms leads to a four-fold higher chance of infection in chronic wounds compared with non-biofilm forming microorganisms (p=0.0001). The presence of biofilm in wounds can also lead to the failure of antibiotics.

Silver ions kill micro-organisms rapidly by blocking enzyme activity associated with respiration, impairing DNA synthesis and affecting cell structure. Silver is also thought to reduce bacterial adhesion and destabilize biofilm as well as increase susceptibility of bacteria to antibiotics. In recent years, a wide range of wound dressings containing elemental silver or silver releasing compounds have been developed and have gained considerable popularity. Silver dressings reduce wound healing times, hospital stays, dressing change frequency, the requirement for analgesia and reduce the number of MRSA-infected wounds. Several systematic literature reviews have been conducted highlighting the positive effects of using silver dressings on chronic wounds One of the most prevalent chronic wounds is venous leg ulcers (VLUs). Chronic leg ulcers affect around 1% (increasing to 4% in elderly populations) of the population, VLUs account for up to 90% of all chronic leg ulcers. Standard treatment of VLUs includes local wound management (e.g. debridement, moist dressings), compression therapy and topical antimicrobials. Despite standard treatment, VLUs are often associated with pain, reduced mobility, an increased risk of infection and extensive healing times. Such effects ultimately contribute to a reduced patient QoL. Only about half of VLUs heal within 4 months and recurrence rate is as high as 57% within the first year. This leaves a significant proportion of non-healing ulcers which place a burden on heath resources and patient QoL. Improvements in healing of VLUs would have a significant impact.

A promising preventative intervention is Negative Pressure Wound Therapy (NPWT), first described in the 1990's NPWT was originally designed for the treatment of open wounds. NPWT consists of a closed sealed system, the wound is covered with a foam or gauze dressing and sealed with an occlusive film. Intermittent or continuous sub-atmospheric pressure is created by a vacuum pump which draws excess fluid from the wound and collects it in a connected waste liquid collector. The system promotes granulation tissue formation, increases tissue blood flow, increases lymphatic clearance and removes bacteria from the wound bed. It therefore has the potential to improve wound outcomes rather than just manage the symptoms. NPWT has been found to be an effective treatment to heal chronic, complex and infected wounds. Recently, NPWT has been recommended in the management of chronic wounds including VLUs.

Being tested
ConvaVAC™ Ag+ Negative Pressure Wound Therapy System
Keywords
Venous Leg Ulcer, Negative Pressure Wound Therapy, Silver ions
Medical subject headings
Varicose Ulcer

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • ConvaVAC™ Ag+ Negative Pressure Wound Therapy SystemDevice

    ConvaVAC™ Ag+ Negative Pressure Wound Therapy System

Study groups in NCT07342049
Study groupRoleWhat they receive
ConvaVAC Ag+ExperimentalNegative Pressure Wound Therapy system
Receives: Device: ConvaVAC™ Ag+ Negative Pressure Wound Therapy System

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Percentage area reduction (PAR) in wound size at day 14

    Difference between wound area at day 0 and day 14 of treatment

    Measured: 14 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 Jan 2026
  2. Study start12 Jan 2026
  3. Primary completion30 Oct 2026 (estimated)
  4. Study completion30 Oct 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
87 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07342049
Sponsor's protocol ID
WC-24-452
Other IDs
359501
Acronym
ConvaVAC VLU
Status last verified
Jul 2026
First submitted
6 Jan 2026
Last updated
9 Jul 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing ConvaVAC™ Ag+ Negative Pressure Wound Therapy System in people with Venous Leg Ulcer (VLU), run by ConvaTec Inc. at 7 sites in 2 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 9 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 7 sites in United Kingdom, Chile. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Percentage area reduction (PAR) in wound size at day 14 (time frame: 14 days). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Jul 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in